Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosiglitazone adjunctive therapy in children with autism spectrum disorder
IRCT20090117001556N150Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of rosiglitazone in Autism Spectrum Disorder (ASD) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoint: Autism severity. Started Jun 2023; status: completed.
02
Drugs
rosiglitazone
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on IRCT20090117001556N150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20090117001556N150.